by Mycoplasma testing includes screening of cell culture, biologics, tissue/organs used for transplantation, and other live biomedical products to ensure safety.
The Global Mycoplasma Testing Market is estimated to be valued at US$ 997.8 Mn in 2024 and is expected to exhibit a CAGR of 9.7% over the forecast period 2024 To 2031.
Key takeaways
Key players operating in the Global Mycoplasma Testing market include Charles River Laboratories International, Merck KGaA, Lonza Group Ltd, Roche Diagnostics, Thermo Fisher Scientific, Merck, InvivoGen, and Creative Bioarray. These companies are focusing on expanding their geographic presence and reaching out to more customers through novel mycoplasma screening and detection products. The increasing demand for biopharmaceuticals is a major factor fueling the growth of the Global Mycoplasma Testing Market. Furthermore, the rising number of clinical research studies involving cell culture is also driving market growth. The market is also witnessing opportunities in emerging economies with the increasing outsourcing of biologics production.
Market key trends
One of the key trends gaining traction in the Global Mycoplasma Testing Market Size is the adoption of digital PCR technology. Digital PCR allows highly sensitive quantification of mycoplasma contamination down to a single copy. It provides accurate quantification without the need for standard curves. This technology overcomes the limitations of traditional PCR methods. Growing acceptance and commercial availability of digital PCR kits and instruments for mycoplasma testing are expected to boost the Global Mycoplasma Testing Market during the forecast period.
Porter’s Analysis
Threat of new entrants: Low costs of production and marketing make entry easy.
Bargaining power of buyers: Few major buyers for suppliers’ products exert strong pressure on prices.
Bargaining power of suppliers: Strong distribution channels allow suppliers to control prices and availability.
Threat of new substitutes: New technologies pose threat of substituting existing products and services.
Competitive rivalry: Intense competition among existing competitors creates pressure to innovate and maintain low prices.
Geographical Regions
North America currently holds the largest share of the global mycoplasma testing market, in terms of value. Availability of state-of-the-art research & development facilities, favorable reimbursement policies, increasing funding for cell-based research, growing biotechnology and pharmaceutical industries are some major factors driving the growth of the mycoplasma testing market in North America.
The Asia Pacific region is expected to witness the highest growth over the forecast period owing to increasing investments by pharmaceutical and biotechnology companies, rising geriatric population, growing collaborations among research institutes and market players. Additionally, rising awareness regarding cell-based research and rapidly increasing healthcare expenditure in Asia Pacific countries are further fueling the demand for mycoplasma testing in this region.
*Note:
1.Source: Coherent Market Insights, Public sources, Desk research
2.We have leveraged AI tools to mine information and compile it
